Literature DB >> 33498794

Coverage with Timely Administered Vaccination against Hepatitis B Virus and Its Influence on the Prevalence of HBV Infection in the Regions of Different Endemicity.

Karen K Kyuregyan1,2, Vera S Kichatova1,2, Olga V Isaeva1,2, Ilya A Potemkin1,2, Elena Yu Malinnikova1,2, Maria A Lopatukhina2, Anastasia A Karlsen1,2, Fedor A Asadi Mobarhan2, Eugeniy V Mullin2, Olga S Slukinova2, Margarita E Ignateva3, Snezhana S Sleptsova4, Elena E Oglezneva5,6, Elena V Shibrik7, Maria G Isaguliants8,9,10, Mikhail I Mikhailov1,2.   

Abstract

Universal hepatitis B vaccination of newborns was implemented in Russia starting from 1998. From 1998 to 2019, the incidence of acute hepatitis B reduced from 43.8 to 0.57 cases per 100,000 population. Here, we assessed the timely coverage of newborns with the birth dose (HepB-BD), second dose (HepB-2nd), and three vaccine doses (HepB3) in two remote regions of Russia with low (Belgorod Oblast) and high (Yakutia) levels of hepatitis B virus (HBV) endemicity. Vaccination data were obtained from the medical records of 1000 children in Yakutia and 2182 children in Belgorod Oblast. Sera of healthy volunteers from Belgorod Oblast (n = 1754) and Yakutia (n = 1072) across all age groups were tested for serological markers of HBV to assess the infection prevalence and herd immunity. Average HepB-BD coverage was 99.2% in Yakutia and 89.4% in Belgorod Oblast (p < 0.0001) and in both regions varied significantly, from 66% to 100%, between medical centers. The principal reason for the absence of HepB-BD was parent refusal, which accounted for 63.5% of cases of non-vaccination (83/123). While timely HepB-2nd coverage was only 55.4%-64.7%: HepB3 coverage by the age of one year exceeded 90% in both study regions. HBV surface antigen (HBsAg) prevalence in the 1998-2019 birth cohort was 0.2% (95% CI: 0.01-1.3%) in Belgorod Oblast and 3.2% (95% CI: 1.9-5.2%) in Yakutia. The proportion of persons testing negative for both antibodies to HBsAg (anti-HBs) and antibodies to HBV core antigen (anti-HBc) in the 1998-2019 birth cohort was 26.2% (125/481) in Belgorod Oblast and 32.3% (162/501) in Yakutia. We also assessed the knowledge of and attitude towards vaccination among 782 students and teachers of both medical and non-medical specialties from Belgorod State University. Only 60% of medical students knew that hepatitis B is a vaccine-preventable disease. Both medical and nonmedical students, 37.8% and 31.3%, respectively, expressed concerns about safety and actual necessity of vaccination. These data indicate the need to introduce a vaccine delivery audit system, improve medical education with respect to vaccination strategies and policies, and reinforce public knowledge on the benefits of vaccination.

Entities:  

Keywords:  HBV prevalence; birth dose coverage; hepatitis B epidemiology; hepatitis B vaccine; public health

Year:  2021        PMID: 33498794      PMCID: PMC7912110          DOI: 10.3390/vaccines9020082

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  19 in total

1.  Hepatitis B vaccines: WHO position paper – July 2017.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-07-07

Review 2.  Sample size estimation in epidemiologic studies.

Authors:  Karimollah Hajian-Tilaki
Journal:  Caspian J Intern Med       Date:  2011

3.  Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles.

Authors:  D Diminsky; N Moav; M Gorecki; Y Barenholz
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

4.  Hepatitis B and the need for a booster dose.

Authors:  Elke Leuridan; Pierre Van Damme
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

5.  Undervaccination with hepatitis B vaccine: missed opportunities or choice?

Authors:  R B Jiles; D Daniels; H R Yusuf; M M McCauley; S Y Chu
Journal:  Am J Prev Med       Date:  2001-05       Impact factor: 5.043

6.  Synthesis and assembly of hepatitis B virus surface antigen particles in yeast.

Authors:  P Valenzuela; A Medina; W J Rutter; G Ammerer; B D Hall
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

7.  Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia.

Authors:  Valeria Ivaniushina; Nadjia Radjef; Marfa Alexeeva; Elyanne Gault; Sergei Semenov; Mohammed Salhi; Oleg Kiselev; Paul Dény
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

8.  Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination.

Authors:  Piyanit Tharmaphornpilas; Aim-orn Rasdjarmrearnsook; Saowanee Plianpanich; Pattaratida Sa-nguanmoo; Yong Poovorawan
Journal:  Vaccine       Date:  2009-08-27       Impact factor: 3.641

9.  A population-based study examining hepatitis B virus infection and immunization rates in Northwest China.

Authors:  Zhaohua Ji; Tingcai Wang; Zhongjun Shao; Dahong Huang; Anhui Wang; Zhiwen Guo; Yong Long; Lei Zhang; Haixia Su; Qi Zhang; Yongping Yan; Daiming Fan
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016.

Authors:  Michael H Le; Yee Hui Yeo; Samuel So; Ed Gane; Ramsey C Cheung; Mindie H Nguyen
Journal:  JAMA Netw Open       Date:  2020-11-02
View more
  2 in total

1.  Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow.

Authors:  Vera S Kichatova; Fedor A Asadi Mobarkhan; Ilya A Potemkin; Sergey P Zlobin; Oksana M Perfilieva; Vladimir T Valuev-Elliston; Alexander V Ivanov; Sergey A Solonin; Mikhail A Godkov; Maria G Belikova; Mikhail I Mikhailov; Karen K Kyuregyan
Journal:  Microorganisms       Date:  2022-02-12

2.  Different evolutionary dynamics of hepatitis B virus genotypes A and D, and hepatitis D virus genotypes 1 and 2 in an endemic area of Yakutia, Russia.

Authors:  Anastasia A Karlsen; Karen K Kyuregyan; Olga V Isaeva; Vera S Kichatova; Fedor A Asadi Mobarkhan; Lyudmila V Bezuglova; Irina G Netesova; Victor A Manuylov; Andrey A Pochtovyi; Vladimir A Gushchin; Snezhana S Sleptsova; Margarita E Ignateva; Mikhail I Mikhailov
Journal:  BMC Infect Dis       Date:  2022-05-12       Impact factor: 3.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.